MLTX240517C30000
- 11.75
- 0.000.00%
MoonLake Immunotherapeutics Newsroom
Buy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development Plans
Express News | MoonLake Immunotherapeutics - Topline Primary Endpoint Readout at Week 16, Together With Data on Other Endpoints, Is Expected as of Mid-2025
Express News | MoonLake Immunotherapeutics Starts Phase 3 Vela Program of the Nanobody® Sonelokimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa
Companies Like MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
MoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial Position
MoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial Position
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)
Express News | MoonLake Immunotherapeutics: Cash, Equivalents, Marketable Debt Securities to Support Roadmap Rich in Potential Catalysts, Cash Runway to End of 2026
MoonLake Immunotherapeutics | 10-Q: Quarterly report
Express News | MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
Express News | MoonLake Immunotherapeutics Q1 EPS USD -0.22
MoonLake Immunotherap 1Q Loss $14M >MLTX
MoonLake Immunotherap 1Q Loss $14M >MLTX
MoonLake Immunotherapeutics | 10-K/A: Annual report (Amendment)
MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating
Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential